Phenotype of spontaneous orofacial dyskinesia in neuregulin-1 'knockout' mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 2, 2009, Pages 330-333

  Tomiyama, Katsunori ^a   O'Tuathaigh, Colm M ^b   O'Sullivan, Gerard J ^b   Kinsella, Anthony ^b   Lai, Donna ^c   Harvey, Richard P ^c   Tighe, Orna ^b   Croke, David T ^b   Koshikawa, Noriaki ^a   Waddington, John L ^b  

^a NIHON UNIVERSITY   (Japan)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

Author keywords

Knockout mice; Neuregulin 1; Orofacial dyskinesia; Phenotype; Schizophrenia; Targeted gene deletion

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; NEU DIFFERENTIATION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; DISEASE PREDISPOSITION; FEMALE; GENE CONTROL; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; INCISOR; JAW MOVEMENT; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OROFACIAL DYSKINESIA; PHENOTYPE; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SOCIOPATHY; TONGUE; TOPOGRAPHY;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; DOPAMINE AGONISTS; JAW; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOVEMENT; MOVEMENT DISORDERS; NEUREGULIN-1; PHENOTYPE; RECEPTORS, DOPAMINE D1; TONGUE;

EID: 60049099124     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.12.010     Document Type: Article

References (22)

1. Arguello P.A., and Gogos J.A. Modeling madness in mice: one piece at a time. Neuron 52 (2006) 179-196
2. Bocti C., Black D.N., and Waddington J.L. Dyskinesia in patients with schizophrenia never treated with antipsychotics: conceptual and pathophysiological implications. In: Bedard M.-A., Agid Y., Chouinard S., Fahn S., Korczyn A.D., and Lesperance P. (Eds). Mental and behavioral dysfunction in movement disorders (2003), Humana Press, Totawa, NJ 489-498
3. Chatterjee A., Chakos M., Koreen A., Geisler S., Sheitman B., Woerner M., et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 152 (1995) 1724-1729
4. Cortese L., Caligiuri M.P., Malla A.K., Manchanda R., Takhar J., and Haricharan R. Relationship of neuromotor disturbances to psychosis symptoms in first-episode neuroleptic-naïve schizophrenia patients. Schizophr Res 75 (2005) 65-75
5. Gogos J.A. Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder. Int Rev Neurobiol 78 (2007) 397-422
6. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10 (2005) 40-68
7. Harrison P.J., and Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 60 (2006) 132-140
8. Kane J.M., and Smith J.M. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39 (1982) 473-481
9. Li D., Collier D.A., and He L. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 15 (2006) 1995-2002
10. Munafo M.R., Thiselton D.L., Clark T.G., and Flint J. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry 11 (2006) 539-546
11. O'Tuathaigh C.M., O'Sullivan G.J., Kinsella A., Harvey R.P., Tighe O., Croke D.T., et al. Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice. NeuroReport 17 (2006) 79-83
12. O'Tuathaigh C.M., Babovic D., O'Meara G., Clifford J.J., Croke D.T., and Waddington J.L. Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behavior. Neurosci Biobehav Rev 31 (2007) 60-78
13. O'Tuathaigh C.M., Babovic D., O'Sullivan G., Clifford J.J., Tighe O., Croke D.T., et al. Phenotypic characterisation of spatial cognition and social behaviour in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 147 (2007) 18-27
14. O'Tuathaigh C.M., O'Connor A.M., O'Sullivan G.J., Lai D., Harvey R.P., Croke D.T., et al. Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous 'knockout' of the schizophrenia risk gene neuregulin-1. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 462-466
15. Stefansson H., Sigurdsson E., Steinhorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Human Genet 71 (2002) 877-892
16. 2-like receptor regulation. Eur J Pharmacol 418 (2001) 47-54
17. 3 receptor "knockout". Synapse 51 (2004) 71-81
18. Tomiyama K., Makihara Y., Yamamoto H., O'Sullivan G., Nally R.E., Tighe O., et al. Disruption of orofacial movement topographies in congenic mutants with dopamine D5 but not D4 receptor or DARPP-32 transduction 'knockout'. Eur Neuropsychopharmacology 16 (2006) 437-445
19. Waddington J.L. Schizophrenia, affective psychoses and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the 'conflict of paradigms'. Int Rev Neurobiol 31 (1989) 297-353
20. Waddington J.L., O'Tuathaigh C., O'Sullivan G., Tomiyama K., Koshikawa N., and Croke D.T. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology 181 (2005) 611-638
21. Waddington J.L., Corvin A.P., Donohoe G., O'Tuathaigh C.M.P., Mitchell K.J., and Gill M. Functional genomics and schizophrenia: endophenotypes and mutant models. Psychiat Clin N Amer 30 (2007) 365-399
22. Whitty P., Owoeye O., and Waddington J.L. Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology. Schizophr Bull (2008) Sept 12 [Electronic Publication ahead of print]